Fortress Biotech Q3 net loss $15M; FDA approved Emrosi on Nov 4; cosibelimab PDUFA Dec 28

Fortress Biotech, Inc.

2024-Q3 EPS reported -$2.43 revenue$42,555,000

Net loss attributable to common stockholders $15.0M ($0.76/shr) vs $7.1M loss in Q3 2023.
Consolidated net revenue $14.6M (all from dermatology products); Q3 2023 revenue $34.8M included $19M license fee.
Cash and equivalents $58.9M as of Sep 30, 2024, down $22M YTD; included $25.6M at Fortress and private subs.
Paused Series A preferred dividends in July 2024, deferring ~$0.7M cash/month; new $35M Oaktree loan terms.
FDA approval of Emrosi on Nov 4; cosibelimab PDUFA date Dec 28; Checkpoint raised $9.2M in Nov warrant exercises.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.